Strategy for personalized immune therapy in HIV-related cryptococcal meningitis
Official title: Strategy Trial of Personalized Immunomodulatory Therapy for HIV-related Cryptococcal Meningitis
Funded at University of Minnesota · NIH-11329210 · Data updated 2026-11-12
This grant tests a personalized immunomodulatory approach to help people with HIV and cryptococcal meningitis improve outcomes.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | September 2, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $331,353 |
| NIH project number | 1U01AI198071-01 |
| Project ID | NIH-11329210 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with HIV who develop cryptococcal meningitis, especially those who are starting or on antiretroviral therapy.
✕Less likely to help
Patients without cryptococcal meningitis or those unable to receive immunomodulatory therapy may not benefit.
What this research studies
This project focuses on HIV-positive individuals who develop cryptococcal meningitis, a serious brain infection. It aims to tailor immune-based treatment alongside antifungal therapy to better control inflammation and improve survival. The study will use biomarkers and patient characteristics to guide therapy choices and optimize outcomes in diverse settings. By integrating immune strategy with standard care, it seeks to reduce mortality and complications in this high-risk population.
Why it matters
Potential benefit: If successful, patients with HIV-related cryptococcal meningitis could have higher survival rates and fewer complications through personalized immune-based treatment.
How similar studies have gone: Previous data suggest that tailoring host immune responses can influence outcomes in HIV-related meningitis, but this exact personalized strategy is novel.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Boulware, David R — University of Minnesota
- Study coordinator: Boulware, David R
Related research
Other NIH-funded projects on the same topics.
-
Personalized Immunomodulatory Therapy for HIV-related Cryptococcal Meningitis
A patient-focused study investigates a personalized treatment approach to improve outcomes for people with HIV who develop cryptococcal meningitis.
-
Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis
A study in Uganda aims to use faster, better tests and a new antifungal to help people with HIV who develop meningitis.
-
TB meningitis diagnostic test compare and cost study in sub-Saharan Africa
Researchers are testing a new CSF urine-based test (SILVAMP TB LAM) to improve diagnosis of TB meningitis in people with HIV, to help speed treatment and reduce death in Sub-Saharan Africa.
-
Minimally Invasive Sampling to Improve HIV-Associated M meningitis Diagnosis in Africa
A research study is testing easier, less invasive ways to diagnose meningitis in people living with HIV, with a focus on making diagnosis faster and more accurate in Africa and the US.
-
Understanding brain injury in kids with tuberculous meningitis (iThemba)
A study in children with TB meningitis in South Africa will look at how inflammation and blood-clotting factors relate to brain injury and infarcts.
-
Serological clues to survival in HIV-related cryptococcal meningitis
This grant looks for antibody signals in the blood that could predict who survives cryptococcal meningitis in people with HIV.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.